Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

217 ARTÍCULOS , VIENDO DEL 1 AL 15

Circular RNAs in Alzheimer's Disease: A New Perspective of Diagnostic and Therapeutic Targets

Vakili O, Asili P, Babaei Z, Mirahmad M, Keshavarzmotamed A, Asemi Z, Mafi A.

CNS Neurol Disord Drug Targets. 2023;22(9):1335-1354. doi: 10.2174/1871527321666220829164211.

Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease

Shah AJ, Mohi-Ud-Din R, Sabreen S, Wani TU, Jan R, Javed MN, Mir PA, Mir RH, Masoodi MH.

Curr Mol Pharmacol. 2023;16(3):254-279. doi: 10.2174/1874467215666220903095837.

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals

Groot C, Smith R, Stomrud E, Binette AP, Leuzy A, Wuestefeld A, Wisse LEM, Palmqvist S, Mattsson-Carlgren N, Janelidze S, Strandberg O, Ossenkoppele R, Hansson O.

Brain. 2023 Apr 19;146(4):1580-1591. doi: 10.1093/brain/awac329.

Ocular Biomarkers for Alzheimer Disease Dementia: An Umbrella Review of Systematic Reviews and Meta-analyses

Costanzo E, Lengyel I, Parravano M, Biagini I, Veldsman M, Badhwar A, Betts M, Cherubini A, Llewellyn DJ, Lourida I, MacGillivray T, Rittman T, Tamburin S, Tai XY, Virgili G.

JAMA Ophthalmol. 2023 Jan 1;141(1):84-91. doi: 10.1001/jamaophthalmol.2022.4845.

Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography

Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, Karikari TK, Lantero-Rodriguez J, Brum WS, Lussier FZ, Bezgin G, Stevenson J, Rahmouni N, Kunach P, Wang YT, Fernandez-Arias J, Socualaya KQ, Macedo AC, Ferrari-Souza JP, Ferreira PCL, Bellaver B, Leffa DT, Zimmer ER, Vitali P, Soucy JP, Triana-Baltzer G, Kolb HC, Pascoal TA, Saha-Chaudhuri P, Gauthier S, Zetterberg H, Blennow K, Rosa-Neto P.

JAMA Neurol. 2023 Feb 1;80(2):188-199. doi: 10.1001/jamaneurol.2022.4485.

Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study

Boerwinkle AH, Gordon BA, Wisch J, Flores S, Henson RL, Butt OH, McKay N, Chen CD, Benzinger TLS, Fagan AM, Handen BL, Christian BT, Head E, Mapstone M, Rafii MS, O'Bryant S, Lai F, Rosas HD, Lee JH, Silverman W, Brickman AM, Chhatwal JP, Cruchaga C, Perrin RJ, Xiong C, Hassenstab J, McDade E, Bateman RJ, Ances BM; Alzheimer's Biomarker Consortium-Down Syndrome; Dominantly Inherited Alzheimer Network.

Lancet Neurol. 2023 Jan;22(1):55-65. doi: 10.1016/S1474-4422(22)00408-2.

Biomarkers of Activity-Dependent Plasticity and Persistent Enhancement of Synaptic Transmission in Alzheimer Disease: A Review of the Current Status

Warpechowski M, Warpechowski J, Kulczyńska-Przybik A, Mroczko B.

Med Sci Monit. 2023 Jan 5;29:e938826. doi: 10.12659/MSM.938826.

Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study

Millar PR, Gordon BA, Luckett PH, Benzinger TLS, Cruchaga C, Fagan AM, Hassenstab JJ, Perrin RJ, Schindler SE, Allegri RF, Day GS, Farlow MR, Mori H, Nübling G; Dominantly Inherited Alzheimer Network; Bateman RJ, Morris JC, Ances BM.

Elife. 2023 Jan 6;12:e81869. doi: 10.7554/eLife.81869.

Plasma biomarkers for neurodegenerative disorders: ready for prime time?

Balogun WG, Zetterberg H, Blennow K, Karikari TK.

Curr Opin Psychiatry. 2023 Mar 1;36(2):112-118. doi: 10.1097/YCO.0000000000000851. Epub 2023 Jan 16.

Shaping the risk for late-life neurodegenerative disease: A systematic review on prenatal risk factors for Alzheimer's disease-related volumetric brain biomarkers

Boots A, Wiegersma AM, Vali Y, van den Hof M, Langendam MW, Limpens J, Backhouse EV, Shenkin SD, Wardlaw JM, Roseboom TJ, de Rooij SR.

Neurosci Biobehav Rev. 2023 Mar;146:105019. doi: 10.1016/j.neubiorev.2022.105019. Epub 2023 Jan 3.

Applications of Alzheimer's disease staging to clinical trials

Therriault J, Gauthier S, Rosa-Neto P.

Aging (Albany NY). 2023 Jan 5;15(1):4-5. doi: 10.18632/aging.204482. Epub 2023 Jan 5.

Experimental approaches for altering the expression of Abeta-degrading enzymes

Loeffler DA.

J Neurochem. 2023 Mar;164(6):725-763. doi: 10.1111/jnc.15762. Epub 2023 Feb 1.

ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aß Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan

Siemers E, Hitchcock J, Sundell K, Dean R, Jerecic J, Cline E, Iverson K, Moore J, Edgar C, Manber R, Fuin N, Poppe T, Barton R.

J Prev Alzheimers Dis. 2023;10(1):19-24. doi: 10.14283/jpad.2022.93.

Priorities for research on neuromodulatory subcortical systems in Alzheimer's disease: Position paper from the NSS PIA of ISTAART

Ehrenberg AJ, Kelberman MA, Liu KY, Dahl MJ, Weinshenker D, Falgàs N, Dutt S, Mather M, Ludwig M, Betts MJ, Winer JR, Teipel S, Weigand AJ, Eschenko O, Hämmerer D, Leiman M, Counts SE, Shine JM, Robertson IH, Levey AI, Lancini E, Son G, Schneider C, Egroo MV, Liguori C, Wang Q, Vazey EM, Rodriguez-Porcel F, Haag L, Bondi MW, Vanneste S, Freeze WM, Yi YJ, Maldinov M, Gatchel J, Satpati A, Babiloni C, Kremen WS, Howard R, Jacobs HIL, Grinberg LT.

Alzheimers Dement. 2023 May;19(5):2182-2196. doi: 10.1002/alz.12937. Epub 2023 Jan 15.

From Association to Intervention: The Alzheimer's Disease-Associated Processes and Targets (ADAPT) Ontology

Daly T, Henry V, Bourdenx M.

J Alzheimers Dis. 2023;94(s1):S87-S96. doi: 10.3233/JAD-221004.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias